Compare SRPT & TSLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SRPT | TSLX |
|---|---|---|
| Founded | 1980 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.8B |
| IPO Year | 2000 | 2011 |
| Metric | SRPT | TSLX |
|---|---|---|
| Price | $22.03 | $18.74 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 29 | 9 |
| Target Price | ★ $25.85 | $21.61 |
| AVG Volume (30 Days) | ★ 2.9M | 475.4K |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 10.82% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.99 | 0.15 |
| Revenue | ★ $2,198,237,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1.20 |
| P/E Ratio | ★ $7.22 | $125.00 |
| Revenue Growth | ★ 15.58 | N/A |
| 52 Week Low | $14.68 | $16.04 |
| 52 Week High | $25.32 | $24.79 |
| Indicator | SRPT | TSLX |
|---|---|---|
| Relative Strength Index (RSI) | 72.39 | 55.78 |
| Support Level | $20.12 | $18.47 |
| Resistance Level | $23.71 | $18.65 |
| Average True Range (ATR) | 1.08 | 0.30 |
| MACD | 0.33 | -0.04 |
| Stochastic Oscillator | 90.82 | 24.66 |
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. The company partners with other companies across a variety of industries and provides creative solutions with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.